Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis - PubMed
2 days ago
- #Multiple myeloma
- #Meta-analysis
- #CAR-T therapy
- Relapsed/refractory multiple myeloma (RRMM) remains a clinical challenge.
- CD38-directed CAR-T therapy, especially dual-target CD38/BCMA constructs, is an emerging immunotherapy.
- This systematic review and meta-analysis evaluated efficacy and safety.
- Four studies with 70 patients included: 3 dual-target (61 patients), 1 single-target (9 patients).
- For dual-target CD38/BCMA CAR-T: pooled ORR 89%, CR/sCR rate 63%, MRD-negative rate 67%, mortality 11%.
- Single-target CD38 CAR-T showed lower efficacy (ORR 33%) and higher mortality (44%).
- Any-grade cytokine release syndrome (CRS) occurred in 83%, grade ≥3 CRS in 26%.
- Other adverse events: infections (23%), ICANS (13%), kidney injury (13%).
- Dual-target CD38/BCMA CAR-T demonstrates promising efficacy and manageable safety.
- Evidence for single-target CD38 CAR-T is limited; further large-scale studies are warranted.